Alps Group Inc: Business Overview, Financials & Competitive Analysis
Alps Group Inc is a fully integrated biotechnology platform specializing in predictive, precision and preventive health management, providing DNA and mRNA sequencing, cellular therapy, and wellness and anti-aging prod...
Cyborg Score thesis
High-growth early-stage biotech with geographic diversification in Asia but challenged profitability and scale...
Read the full analyst-debate transcript →Get the Latest Alps Group Inc Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeAlps Group Inc Overview
Pro stress-test →Alps Group Inc is a fully integrated biotechnology platform specializing in predictive, precision and preventive health management, providing DNA and mRNA sequencing, cellular therapy, and wellness and anti-aging products and services. The company began trading on the Nasdaq Global Market under the ticker symbol "ALPS" in October 2025 following a business combination with Globalink Investment Inc.
Strategic Profile
Pro stress-test →In fiscal year 2026, Alps achieved 44% revenue growth to $4.9 million, led by cellular therapy, medical testing, laboratory and aesthetics beauty services, and healthcare products. The company integrates cutting-edge research, manufacturing, and clinical innovation to drive next-generation healthcare solutions that are accessible and affordable across Southeast Asia and beyond.
Competitive Landscape
Pro stress-test →Alps competes in the precision medicine and wellness sectors, offering DNA/mRNA sequencing, cellular therapy, and anti-aging services. Key competitors include larger integrated biotech and diagnostics platforms focused on genomic testing, cell therapy, and preventive health management, as well as beauty and wellness providers operating in similar markets across Southeast Asia and developed regions.
Industry Context
Alps Group Inc operates in Stem Cell Therapy.
Key facts
Founded: 2017 · Headquarters: Kuala Lumpur, Malaysia · Employees: 93 · Revenue: $4.9M (FY2026, ended March 31, 2026); FY2025 $3.4M · Market cap: $75M–$120M (volatile; $0.56–$15.00 range)